COPENHAGEN, Denmark--(BUSINESS WIRE)--DELL INNOVATION DAY — Dell today announced its extended partnership with Translational Genomics Research Institute (TGen) to help clinical researchers and doctors globally expand the reach and impact of the world’s first Food and Drug Administration (FDA)-approved personalized medicine trial for pediatric cancer. The renewed commitment includes an additional $3 million Dell grant to support continued collaboration with TGen and support the Neuroblastoma and
| < Prev | Next > |
|---|
